ICURe TopMD Pathway Biomarker Catalogue

在这个项目中，我们正在开发一个目录，跨越疾病和治疗，新的，更强大的和信息丰富的生物标志物，用作伴随诊断，以预测个体患者的治疗反应，并提高药物开发和测试的效率。我们的人工智能增强技术，TopMD，是在大学开发的，创新性地使用已知的生物学途径作为坐标来测量全局基因表达的“形状”，准确地代表两种分子表型作为一个强大的“途径生物标志物”。与制药公司和医疗保健提供者的讨论确定我们的目标是将创新技术的价值最大化。在Innovate UK ICURe市场验证项目选项圆桌会议上，一个专家小组建议我们“分拆”一家公司，并创建一个TopMD途径生物标志物库，作为生物标志物产品的网络目录。该项目将提供疾病和治疗诱导基因表达的TopMD途径生物标志物库。TopMD分类诊断疾病和疾病亚型的准确性将通过同行评审进行评估和发布。这些图书馆将作为“路径标记”的高价值目录，将TopMD定位为精准医学的全球领导者，并满足政府2/4的重大挑战：人工智能和数据以及健康老龄化。

In this project, we are developing a catalogue, across diseases and treatments, of new, more powerful and informative biomarkers for use as companion diagnostics to predict treatment response in individual patients and for improving the efficiency of the development and testing of medicines.Our AI-enhanced technology, TopMD, was developed at the University, innovatively uses known biological pathways as coordinates for measuring the 'shape' of global gene expression, accurately representing both the molecular phenotype as a robust 'pathway biomarker'.Discussions with pharmaceutical companies and healthcare providers identified routes to market to maximise the value promised by this innovative technology. We were advised by a panel of experts at the Innovate UK ICURe market validation programme options roundabout to 'spin-out' a company, and create a library of TopMD pathway biomarkers as a networked catalogue of biomarker products.This project will deliver libraries of TopMD pathway biomarkers of disease and treatment-induced gene expression. The accuracy of TopMD classification diagnosis of diseases and disease sub-types will be assessed and published via peer review. The libraries will act as high value catalogues of 'pathway biomarkers', positioning TopMD as a global leader in Precision Medicine and meeting 2/4 of the government grand challenges; AI & Data and Healthy ageing.